Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes
Diabetes mellitus (DM) is a persistent and steadily progressing metabolic condition distinguished by unregulated high levels of blood glucose. GLP1 receptor agonists have recently gained recognition as first-line therapies in selected instances, as per the updated ADA guidelines, highlighting their...
Saved in:
Main Authors: | Jie Luo, Yilin Fang, Zhanghua Qi, Fengyang Cui, Hong Hu, Shengjie Li, Tingtao Chen, Hongyan Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/cjid/6675676 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats
by: Artur Dembiński, et al.
Published: (2016-01-01) -
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
by: María Isabel del Olmo-Garcia, et al.
Published: (2018-01-01) -
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01) -
Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists
by: Mayeesha Ahmed, et al.
Published: (2025-02-01) -
Nutrient Induced Type 2 and Chemical Induced Type 1 Experimental Diabetes Differently Modulate Gastric GLP-1 Receptor Expression
by: Olga Bloch, et al.
Published: (2015-01-01)